Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
Industry, Sector and Symbol
Stock Exchange ETR
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
SymbolETR:GXI
CUSIPN/A
Phone+49-211-618100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins10.26%
Return on Equity20.68%
Return on Assets6.56%
Miscellaneous
EmployeesN/A
Outstanding Shares31,400,000
Market Cap$2.10 billion
Gerresheimer (ETR:GXI) Frequently Asked Questions
What is Gerresheimer's stock symbol?
Gerresheimer trades on the ETR under the ticker symbol "GXI."
What price target have analysts set for GXI?
12 analysts have issued 12-month target prices for Gerresheimer's stock. Their forecasts range from €60.00 to €88.00. On average, they expect Gerresheimer's share price to reach €73.36 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for Gerresheimer.
What is the consensus analysts' recommendation for Gerresheimer?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gerresheimer in the last year. There are currently 2 sell ratings, 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Gerresheimer.
Who are some of Gerresheimer's key competitors?
Some companies that are related to Gerresheimer include Ansell (ANN), Enerplus (ERF), Advanced Medical Solutions (AMS), TransEnterix (TRXC), CRH Medical (CRH), CRH Medical (CRHM), Tristel (TSTL), TSO3 (TOS), Clover (CLV), Bovie Medical (BVX), InfuSystem (INFU), Retractable Technologies (RVP), Milestone Scientific (MLSS), IsoRay (ISR) and Akers Biosciences (AKR).
Who are Gerresheimer's key executives?
Gerresheimer's management team includes the folowing people:
- Mr. Rainer Beaujean, Speaker of the Management Board & CFO (Age 50)
- Mr. Andreas Schutte, Member of the Management Board (Age 56)
- Ms. Katja Schnitzler, Group Director of Bus. Excellence & Continuous Improvement and Member of the Supervisory Board (Age 37)
- Dr. Lukas Burkhardt, Member of Management Board (Age 39)
- Ms. Severine Camp, Corp. Sr. Director of Investor Relations
Has Gerresheimer been receiving favorable news coverage?
Media stories about GXI stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gerresheimer earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave news headlines about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Gerresheimer.
What is Gerresheimer's stock price today?
One share of GXI stock can currently be purchased for approximately €71.20.
How big of a company is Gerresheimer?
Gerresheimer has a market capitalization of $2.10 billion.
How can I contact Gerresheimer?
Gerresheimer's mailing address is Klaus-Bungert-Strasse 4, DUESSELDORF, 40468, Germany. The company can be reached via phone at +49-211-618100.
MarketBeat Community Rating for Gerresheimer (ETR GXI)
MarketBeat's community ratings are surveys of what our community members think about Gerresheimer and other stocks. Vote "Outperform" if you believe GXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
